Brent Vaughan(@brent_vaughan) is CEO of @CognitoTx, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease.

e-Meet Brent at #Sachs_NIF pic.twitter.com/2buParUbrt

— Sachs Associates (@SachsAssociates) March 17, 2021